BrightHeart, a Paris-based AI company focused on obstetrics and pediatric cardiology, has demonstrated breakthrough results in improving detection of congenital heart defects (CHDs) during prenatal ultrasounds. The company also recently received FDA clearance for its innovative AI technology.
BrightHeart’s AI for Prenatal Heart Defect Detection Receives FDA Clearance
Previous
Previous
AI assistance improves CHD detection on prenatal ultrasound
Next
Next